Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...

GSK stock plunged Wednesday after sales of its RSV vaccine, Arexvy, skidded and widely missed Wall Street's expectations.

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

To hear GSK CEO Emma Walmsley tell it, the third quarter presented “some challenges” for the drugmaker. | To hear GSK CEO ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...

GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...

GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated ...

Investing.com -- Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming ...